The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.

JS, Hyams; M, Dubinsky; J, Rosh; FM, Ruemmele; SF, Eichner; JF, Maa; A, Lazar; G, Alperovich; NM, Mostafa; AM, Robinson

doi:10.1111/apt.15054

Public

The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.

Shared by NobleBlocks on Dec 2, 2018 • 12:00 AM UTC

Authors:

Hyams JS

Dubinsky M

Rosh J

Abstract

<h4>Background</h4>In the IMAgINE 1 study, adalimumab induced and maintained remission of moderate-to-severe Crohn's disease in children.<h4>Aim</h4>To assess the efficacy, pharmacokinetics, immunogenicity and safety of immunomodulator and adalimumab combination therapy vs adalimumab monotherapy in ...

Discussions